Why Did QNCX Stock Surge 40% In Pre-Market Today?

The company cleared a key debt obligation with the European Investment Bank, a move allowing it to pursue strategic restructuring.

Tariff uncertainty has prompted several analysts to cut their price targets for Five9 stock.

Trending stock. (Photo Courtesy of Flavio Coelho via Getty Images)

Arnab Paul·Stocktwits

Published Mar 30, 2026 | 9:07 AM EDT

Add us on

Shares of Quince Therapeutics (QNCX) shot up more than 40% in pre-market trading on Monday after the company announced it has settled its debt with the European Investment Bank, a move that clears the way for advancing its restructuring efforts.

Quince Therapeutics said it paid $5.5 million and, as a result, has settled its total debt worth $16.4 million. With this payment, all commitments under both the loan and settlement agreements have been fully satisfied.

“By settling Quince’s debt obligations, we believe that we have removed a substantial overhang that was constraining the company’s flexibility and ability to pursue strategic alternatives, including, but not limited to, merger, reverse merger, asset sale, or other strategic transactions,” said CEO Dirk Thye.

Get updates to this developing story on Stocktwits.

For updates and corrections, email newsroom[at]stocktwits[dot]com.